IQInvest research note
12 OCT 2026 · 07:12 ET
REGN
Regeneron Pharmaceuticals, Inc.
$746.54
$6.97 (+0.94%)up 0.94%
12 October 2026 · delayed 15+ min
D+
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Regeneron Pharmaceuticals, Inc. earns a D+ on excellent profit margins (>20%) and strong current ratio (>2.0) but high debt-to-equity ratio (>2.0) and negative earnings growth. Reasonable investment with moderate upside potential.
Adjusted for Moderate investors, Medium-term investors 5.1% suggested allocation Change these
IQ-REGN-20261012engine v1 · 7-category weighted scorecard